Cost-effectiveness of twice-daily indacaterol/glycopyrrolate inhalation powder for the treatment of moderate to severe COPD in the US. [electronic resource]
Producer: 20190701Description: 3867-3877 p. digitalISSN:- 1178-2005
- Administration, Inhalation
- Adrenergic beta-2 Receptor Agonists -- administration & dosage
- Bronchodilator Agents -- administration & dosage
- Cost-Benefit Analysis
- Drug Administration Schedule
- Drug Combinations
- Drug Costs
- Forced Expiratory Volume
- Glycopyrrolate -- administration & dosage
- Humans
- Indans -- administration & dosage
- Lung -- drug effects
- Markov Chains
- Models, Economic
- Muscarinic Antagonists -- administration & dosage
- Nebulizers and Vaporizers -- economics
- Powders
- Pulmonary Disease, Chronic Obstructive -- diagnosis
- Quinolones -- administration & dosage
- Randomized Controlled Trials as Topic
- Severity of Illness Index
- Time Factors
- Treatment Outcome
- United States
No physical items for this record
Publication Type: Comparative Study; Journal Article
There are no comments on this title.
Log in to your account to post a comment.